Lakefront Biotherapeutics NV (AMS:LKFT)
| Market Cap | 2.00B +7.2% |
| Revenue (ttm) | 990.57M +259.4% |
| Net Income | 596.64M |
| EPS | 9.05 |
| Shares Out | 64.02M |
| PE Ratio | 3.45 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 114,956 |
| Open | 30.58 |
| Previous Close | 30.18 |
| Day's Range | 30.58 - 31.88 |
| 52-Week Range | 22.32 - 32.00 |
| Beta | 0.01 |
| Analysts | Hold |
| Price Target | 32.61 (+4.45%) |
| Earnings Date | Nov 11, 2026 |
About AMS:LKFT
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relaps... [Read more]
Financial Performance
In 2025, AMS:LKFT's revenue was 1.11 billion, an increase of 303.50% compared to the previous year's 275.65 million. Earnings were 320.88 million, an increase of 333.15%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for LKFT stock is "Hold." The 12-month stock price target is €32.61, which is an increase of 4.45% from the latest price.
News
Lakefront Biotherapeutics price target raised to $27 from $26 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on Lakefront Biotherapeutics (LKFT) to $27 from $26 and keeps an Equal Weight rating on the shares. Published first on…
Lakefront Biotherapeutics initiates EUR 50M share repurchase program
Lakefront Biotherapeutics (LKFT) announced the initiation of a new share repurchase program of up to EUR 50M, following completion of its initial EUR 50M program announced on June 9. Under…
Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program
Mechelen, Belgium; November 16, 2026; 7.30 AM CET regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the initiation of a new share repurchase program of up ...
Lakefront Biotherapeutics NV Earnings release: Q3 2026
Lakefront Biotherapeutics NV released its Q3 2026 earnings on November 13, 2026, summarizing the period's financial results.
Lakefront Biotherapeutics NV Earnings release: Q3 2026
Lakefront Biotherapeutics NV released its Q3 2026 earnings on November 13, 2026, summarizing the period's financial results.
Galapagos NV Reports Nine Months 2026 Financial Results and Announces Second €50 million Share Repurchase Program
Galapagos NV (operating as Lakefront Biotherapeutics NV) reported its financial results for the first nine months of 2026 and provided a business update. The company reported a net profit of €13.9 mil...
Lakefront Biotherapeutics Reports Nine Months 2026 Financial Results and Provides Business Update
Gamgertamig poster accepted for presentation at the 2026 ASH 1 Annual Meeting, featuring data from ongoing Phase 1b studies that suggest potential to retain remission after B cell reconstitution, main...
Lakefront to Present at the 2026 Jefferies Global Healthcare Conference in London
Mechelen, Belgium; November 10, 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the 2026 Jefferies Global Healthca...
Lakefront Biotherapeutics NV Slides: Corporate presentation
Lakefront Biotherapeutics NV has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
Galapagos NV Announces Gamgertamig Preliminary Phase 1b Data and Poster Presentation at 2026 ASH Meeting
Galapagos NV announced the acceptance of a poster presentation at the 2026 American Society of Hematology Annual Meeting, scheduled for December 12-15, featuring preliminary data for gamgertamig in re...
Lakefront Biotherapeutics Announces Poster Presentation at the 2026 American Society of Hematology Meeting
Gamgertamig data from ongoing Phase 1b studies suggest potential to retain remission after B cell reconstitution, maintained in the absence of background therapy for autoimmune cytopenias, consistent ...
Lakefront Biotherapeutics Welcomes Dr. Mehdi Shahidi to its Board of Directors
Dr. Shahidi brings extensive drug development experience, regulatory success, and transformative operational expertise to the Board
Lakefront sells early-stage cell therapy pipeline to Armed Cell for $8M upfront
Lakefront Biotherapeutics (LKFT) announced that it has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotechnology company developing next-...
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
Previously announced wind-down of the legacy cell therapy activities is substantially complete Mechelen, Belgium; October 14, 2026, 22.01 CEST; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ...
Acquisition of Own Shares
Mechelen, Belgium; October 13, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) (...
Lakefront upgraded to Outperform from Sector Perform at RBC Capital
RBC Capital upgraded Lakefront Biotherapeutics (LKFT) to Outperform from Sector Perform with a price target of $45, up from $26. The firm sees a “meaningful opportunity” for gamgertamig in rare…
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
Lakefront Biotherapeutics American Depositary Shares NASDAQ: LKFT said it plans to begin registrational studies next year for its lead T-cell engager, gamgertamig, following a broad restructuring of i...
Lakefront Biotherapeutics NV Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has undergone a major transformation, focusing on T-cell engagers and securing gamgertamig as a lead asset with Gilead as a key partner. Registration studies in autoimmune diseases are set for next year, supported by strong financials and a robust pipeline. Regulatory and industry trends are favorable.
Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Mechelen, Belgium; 8 September 2026, 22.01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the Company will host a fireside chat at the Morgan Stanley 24th Annual Glob...
Lakefront Biotherapeutics granted orphan drug designation for gamgertamig
Lakefront Biotherapeutic (LKFT) announced that the FDA has granted orphan drug designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan ...
U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus
Mechelen, Belgium; 24 August 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that the U.S. Food and Drug Administration (FDA) has grante...
Lakefront Receives Transparency Notification from Bank of America
Mechelen, Belgium; August 24, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) received a transparency notification from Bank of America.
Lakefront Biotherapeutics price target lowered to $26 from $30 at Morgan Stanley
Morgan Stanley analyst Judah Frommer lowered the firm’s price target on Lakefront Biotherapeutics (LKFT) to $26 from $30 and keeps an Equal Weight rating on the shares. The firm updated…
Lakefront Biotherapeutics NV Earnings release: Q2 2026
Lakefront Biotherapeutics NV released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Lakefront Biotherapeutics NV Quarterly report: Q2 2026
Lakefront Biotherapeutics NV has published its Q2 2026 quarterly earnings report on August 11, 2026.